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The tumour microenvironment plays a key role in 
cancer growth and metastasis. Whilst it is likely that the 
cells and extracellular matrix (the tumour stroma) 
underlying an epithelial malignancy are initially hostile 
to tumour infiltration, it is becoming clear that stromal 
adaptations take place in response to contextual cues 
which ultimately enable tumour dissemination [1]. The 
predominant cellular component of the tumour stroma, 
the fibroblast, undergoes complex and heterogeneous 
phenotypic alterations, often referred to collectively and  
 
 









































non-specifically as ‘activation’ [2]. This term covers a 
range of cancer-associated fibroblast (CAF) phenotypes 
that are supportive of, and possibly hostile to, tumour 
invasion, the molecular aetiology of which is poorly 
understood.   
 
A great deal of attention has been paid to the concept of 
α-smooth muscle actin positive ‘myofibroblastic’ CAF 
[3], but it has become clear that this is not the only CAF 
phenotype. Senescent CAF are also present in the tumour 
microenvironment [4] as well as in premalignant lesions 
[5-8] including those that precede the development of 




























phosphatase  and  tensin  homologue  (PTEN).  Additionally,  elevated  levels  of  cyclo‐oxygenase  2  (PTGS2;  COX‐2)  and
prostaglandin E2  (PGE2) secretion were observed  in senescent  fibroblasts, and  inhibition of COX‐2 by celecoxib reduced
the expression of miR‐335, restored PTEN expression and decreased the pro‐tumourigenic effects of the SASP.  Collectively
these  data  demonstrate  the  existence  of  a  novel  miRNA/PTEN‐regulated  pathway  modulating  the  inflammasome  in
senescent fibroblasts. 
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neoplasia in oral sub-mucosal fibrosis [8]. These 
senescent cells, characterized by having undergone 
irreversible growth arrest but remaining metabolically 
active, generate an enhanced and altered secretome 
termed the senescence-associated secretory phenotype 
(SASP) [9]. The SASP, which contains elevated levels of 
growth factors, cytokines, ECM components and other 
factors, contributes to the generation of a pro-
inflammatory, pro-metastatic extracellular milieu [9]. 
During oncotherapy most anti-cancer drugs, such as 
cisplatin, induce either apoptosis or senescence of cancer 
cells to suppress tumour growth [10, 11] and this may 
also provoke senescence in the neighbouring stroma [12], 
with detrimental effects [13]. SASP mediated cross-talk 
between stroma and cancer cells may, therefore, be 
critical in determining the success and failure rates of 
chemotherapy and influence the development of 
chemotherapy resistance, disease recurrence or 
progression, and ultimately, patient survival. 
 
Senescent CAF are likely to predominantly develop from 
resident fibroblasts in response to micro-environmental 
insults (such as reactive oxygen species generated by 
aberrant metabolic activity in cancer cells), as well as 
those derived from the environment (such as irradiation, 
chemotherapy and cigarette smoke) and natural aging 
[14]. The molecular mechanisms underlying the 
development of the resulting pro-tumourigenic SASP, 
however, remain poorly understood. Elucidating the 
mechanisms responsible for generating the SASP could 
have translational benefits since stromal fibroblasts are 
generally believed to be genetically stable [15] and 
therefore less vulnerable to developing resistance to 
therapy, a significant problem with the pharmacological 
targeting of genetically unstable tumour cells. 
 
Here we show that the development of an inflammatory 
SASP by fibroblasts induced to senesce by cisplatin and 
other DNA damaging agents or aging, as well as in 
innately senescent CAF, is stimulated by miR-335 and 
regulated by COX-2 and PTEN. Collectively our data 
suggest that combined targeting of COX-2 and 
signaling downstream of PTEN, in association with 
conventional chemotherapy, may ameliorate the pro-





Cisplatin induces senescence in primary oral 
fibroblasts and provokes the development of a pro-
tumourigenic SASP 
 
Although it has been reported that primary human oral 
fibroblasts are able to develop a senescence-associated 
secretory phenotype (SASP), the constituents of this 
have not previously been characterized and the ability 
of chemotherapeutics to induce the SASP in these cells 
has not been explored. In order to address these 
questions, fibroblasts were exposed to DNA damaging 
agents (H2O2 and cisplatin), or cultured to replicative 
senescence and the composition of the resulting 
secretome was analysed. Successful induction of 
senescence was demonstrated by positive senescence-
associated (SA) β-galactosidase staining (Fig 1A), 
elevated p16INK4A levels (Fig 1B) and increased levels of 
p21CIP1 (Fig 1C). Analysis of conditioned media 
collected from prematurely senescent fibroblasts up to 
15 days after induction of senescence revealed increased 
pro-matrix metalloproteinase 2 (pro-MMP2) activity 
(Fig S1A-C) and widespread alterations in the 
constituents of the SASP compared to proliferating 
controls (Fig 1D). Increased expression and secretion of 
IL-6 and MCP-1 in senescent cells were confirmed by 
qRT-PCR (except replicative senescence) and ELISA, 
respectively (Fig S1D-G). All secreted proteins were 
normalized to fibroblast cell density. Senescent 
fibroblasts also displayed increased α-SMA positive 
actin filaments compared to proliferating controls (Fig 
S1H). Conditioned media from senescent fibroblasts 
stimulated proliferation, chemotaxis and invasion of 
dysplastic (pre-malignant) keratinocytes and malignant 
epithelial cells (Fig 2A-E and Fig S2A-B). 
Incorporation of senescent fibroblasts into an 
organotypic model of the malignant oral mucosa [16] 
increased the invasive index of non-metastatic H357 
[17] cancer cells (Fig 2F). 
 
Widespread changes in miRNA expression are 
associated with the development of the SASP 
 
Profiling of cDNA synthesized from RNA extracted 
from senescent fibroblasts, 15 days after induction of 
senescence with cisplatin, revealed widespread changes 
in miRNA expression levels (Fig 3A and Table S1), 
including elevated miR-146a, a microRNA previously 
reported to be associated with secretion of inflammatory 
cytokines by senescent fibroblasts [18]. Following 
validation of changes in candidate miRNA expression 
in a number of cultures, and assessment of expression 
changes in fibroblasts induced to senesce by different 
stimuli (H2O2 and replicative exhaustion) by qPCR, 
miR-335-5p (thenceforth referred to as miR-335) was 
selected for further analysis (Fig S3A-C). Elevated 
levels of miR-335 were previously reported in aged 
human tissues and found conserved across species [19, 
20]. Its over-expression induced premature ageing in 
human sarcoma cell lines and mesenchymal stem cells 
[21, 22].  We observed that miR-335 was significantly 
up-regulated in senescent fibroblasts irrespective of the 
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method of senescence induction, and the time course of 
induction of miR-335 was in accordance to that of IL-6, 
MCP-1 and increased catalytic activity of MMP-2 (Fig 
3B-D, Fig S1A), suggesting that miR-335 was a 
putative candidate as a regulator of SASP development. 
Accordingly, heterologous over-expression of miR-335 
increased the expression and secretion of a panel of 
SASP markers including MCP-1 (rho=0.75, p-
value=0.03), IL-6 (rho=0.95, p-value=0.0002) and 
MMP-2 (rho=0.7, p-value=0.035)  (Fig 3E-H, Fig S3D). 
Over-expression of miR-335 in fibroblasts increased 
migration and invasion of malignant H357 cells in 
indirect co-culture (Fig 3I-J). No effect was observed on 
the acquisition of senescence assessed by the levels of 
p21CIP1 and p16INK4a (Fig S3E-F) and negative SA-β-
Gal activity (data not shown), consistent with previous 
reports by Campisi and colleagues that senescence and 
the development of SASP are two independent events 




































to stimulate chemotaxis of oral cancer cells [24, 25], we 
examined the effects of functionally blocking MCP-1 in 
miR-335 overexpressing fibroblasts on the migration 
and invasion of cancer cells. Blockade of secreted 
MCP-1 in conditioned media from senescent fibroblasts 
significantly attenuated the migration and invasion of 
H357 cells (Fig 3K, Fig S3G). Blockade of secreted 
MCP-1 in conditioned media of proliferating fibroblasts 
also produced a profound reduction in migration and 
invasion of H357 cells in co-culture, suggesting MCP-1 
also plays a role in communication between proliferating 
fibroblasts and cancer cells. Alternatively, it is also 
plausible that within the proliferating population there 
exists a subset of MCP-1 secreting senescent fibroblasts, 
which stimulate cancer cell migration. Inhibition of 
MCP-1 in conditioned media of oral fibroblasts over-
expressing miR-335 significantly reduced chemotaxis of 
H357 cells compared to control cells transfected with a 






































Figure  1.  Genotoxic  stress  induces  a  pro‐inflammatory  SASP  in  normal  human  oral  fibroblasts.  Senescence‐associated  β‐
galactosidase activity (A) was measured in human oral fibroblasts treated with hydrogen peroxide (H2O2) and cisplatin at day 15 post‐treatment
and  in  replicative  senescent and untreated presenescent  control  cells  (n=4). qRT‐PCR  showed  senescent  fibroblasts expressed more  cyclin
dependent  kinase  inhibitor  (CDKI): p16INK4A  (B) and p21CIP1  (C)  than presenescent  controls  (n=4). The heat‐map demonstrates  the  cytokine



















































































































Figure  2.  The  SASP  engenders  a  protumourigenic  phenotype  to  the  senescent  oral  fibroblasts.  Soluble  factors
secreted by  senescent  fibroblasts  stimulated proliferation and migration of D20  (A‐B) and H357  cell  lines  (C‐D)  in 2D assay
(n=3). The  invasiveness of H357 cells was also  increased by senescent fibroblasts  in both 2D and 3D organotypic models (E‐F)
(n=3). Immunohistochemistry for p16INK4A was performed in paraffin embedded sections of 3D organotypic models to confirm
presence of senescent  fibroblasts  (F,  left  lower panel). All experiments were performed  independently as  indicated by n and
with technical repeats. The bars represent mean ± SEM. *p<0.05, was determined by one‐way ANOVA with post‐hoc correction
by  Tukey  test  (B)  and  Dunn’s method  (D‐E).  Two‐way  repeated measure  ANOVA  was  performed  to  determine  statistical
significance in proliferation assay (A, C) with post‐hoc correction by Holm‐Sidak method. (See Supplementary Figure S2).  
  
















































































































Figure 3. Senescent oral  fibroblasts differentially express SASP‐associated miRNAs.  The  volcano plot  illustrates  the differentially
expressed miRNA signature  in cisplatin  induced senescent oral fibroblasts. cDNA synthesized from RNA  isolated from proliferating fibroblasts
and fibroblasts induced to senesce using cisplatin (RNA isolated 15 days post‐senescence) was analyzed using TaqMan miRNA tiling low density
array  (TLDA)  to determine miRNA expression profile  in  senescent  fibroblasts  (n=3)  (A).   qRT‐PCR  showed  that miR‐335  (B)  levels gradually
increase  in senescent fibroblasts with a time course corresponding to the  increase  in the  levels of SASP components  IL‐6 (C) and MCP‐1 (D),
(n=3). Over‐expression of miR‐335  in  young  fibroblasts  increased  synthesis  and  secretion of MCP‐1  (E‐F)  and  IL‐6  (G‐H)  (n=3),  and  stimulated
chemotaxis and invasion of H357 cells in 2D‐assay (n=3) (I‐J). Blockade of MCP‐1 in conditioned media of senescent fibroblasts significantly reduced
migration of H357 cells compared to negative isotype IgG treated control (n=3) (K). Blockade of MCP‐1 in conditioned media derived from miR‐335
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miR-335 targets PTEN to sustain elements of the SASP 
 
In silico pathway analysis revealed that the 
phosphoinositide 3-kinase (PI3-K) and Akt signaling 
pathway ranked highest amongst fifty other pathways 

















































to be targeted by twenty-eight of the differentially 
expressed miRNAs including miR-335 (Table S2, Fig 
S4A-B). PTEN, a regulator of PI3-K and Akt signalling 
previously reported to be involved in stromal-tumour 
interactions and senescence [26, 27], is a putative 




















































manner  (n=3)  (B). Co‐transfection of miR‐335 with pmiR‐reporter  vector bearing  a  1.45  kb  insert of PTEN  3’UTR  showed diminished
luminescence compared to controls (n=3)   (C). Western blot showed PTEN expression  is reduced  in senescent fibroblasts, compared to
presenescence (proliferating) controls (n=9) (D) and this is associated with an increased phosphorylation of Akt (E). Transient knockdown
of  PTEN  in  oral  fibroblasts  stimulated  transmigration  of  H357  cells  in  vitro  (n=3)  and  increased  MMP2  transcript  levels  (F‐H).  All
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other miRNAs identified as up-regulated in senescent 
cells displaying a robust SASP (Fig 4A, Table S3). 
Over-expression of miR-335 caused a dose-dependent 
decrease in PTEN protein levels in primary oral 
fibroblasts (Fig 4B) and suppressed luciferase 
expression from a construct containing the firefly 
luciferase coding region directly 5’ upstream of a 
fragment of the PTEN 3’UTR containing the putative 
binding sites for miR-335 (Fig 4C). Analysis of PTEN 
expression in senescent fibroblasts revealed a 
significant decrease compared to proliferating cells 
irrespective of the method of senescence induction (Fig 
4D). This reduction was independently confirmed by 
RNA-seq analysis of transcriptomic changes in 
senescent fibroblasts compared to proliferating controls 
(Mellone et al, manuscript in submission). Increased 
Akt phosphorylation (indicative of reduced PTEN 
function) was also observed in senescent fibroblasts 
(Fig 4E). Transient knockdown of endogenous PTEN 
using siRNA enhanced the capacity of normal oral 
fibroblasts to stimulate chemotaxis of malignant cells in 
vitro  (Fig 4F-G) accompanied by a significant increase 
in secretion of the SASP marker MMP-2 (Fig 4H) and a 
trend towards increasing IL-6 levels (p=0.360) (Fig 
S4C).  
 
COX-2 signalling promotes miRNA-mediated PTEN 
reduction and drives the development of the SASP 
 
Elevated prostaglandin (PGE2) production by COX-2 is 
known to be a feature of senescent cells [28], and 
recombinant PGE2 can induce senescence in fibroblasts 
[28-30]. COX-2-regulation of the PTEN/Akt signalling 
is well documented in osteoblasts [31] but its role in 
fibroblasts is less well understood [32, 33]. The 
beneficial effects of using nonselective cyclooxygenase 
inhibitors in combination with chemotherapy [34] 
compelled us to examine whether COX-2 activity 
played a role in modulating the SASP in primary oral 
fibroblasts. We analyzed the levels of COX-2 transcript 
and the secreted product of its catalytic activity, PGE2, 
in fibroblasts induced to senesce by cisplatin or H2O2, 
and in replicative senescent cells. COX-2 transcripts 
were higher in senescent fibroblasts than proliferating 
controls and this was associated with elevated levels of 
secreted PGE2 in conditioned media isolated from 
senescent cells (Fig 5A-B). IL-6 is characterized as a 
COX-2-dependent cytokine necessary to activate 
numerous oncogenic signals acting downstream of 
COX-2 in cancer cells via activating STAT3 (signal 
transducer and activator of transcription 3) [35]. 
Selective inhibition of COX-2 activity with celecoxib in 
senescent fibroblasts significantly constrained the 
release of PGE2 and SASP component IL-6, and 
diminished chemotaxis of cancer cells in vitro to levels 
similar to those of untreated proliferating control (Fig 
5C-E). Celecoxib also inhibited cancer cell migration 
towards conditioned media of proliferating fibroblasts to 
a greater extent than its senescent counterparts indicating 
the presence of other COX-2 and IL-6 independent SASP 
components in the conditioned media of senescent 
fibroblasts (Fig 5D, Fig S5A-B). Celecoxib neither 
induced senescence in proliferating fibroblasts nor altered 
SA β-activity of senescent fibroblasts (Fig S5C). In 
contrast celecoxib reduced expression of miR-335 in 
senescent fibroblasts compared to proliferating controls 
and this was associated with restoration of PTEN 
expression (Fig 5F-G).  
  
A COX-2 stimulated miR-335/PTEN regulated 
SASP exists in senescent cancer-associated 
fibroblasts 
 
We have previously reported that CAF isolated from 
aggressive, genetically unstable, squamous cell 
carcinomas have a predominantly senescent phenotype 
[4]. We next utilized this knowledge to examine 
whether a COX-2/miR-335/PTEN signaling cascade 
contributes to the development of the SASP associated 
with senescent CAF as well as normal fibroblasts 
induced to senesce. Even though these CAF does not 
bear any genetic abnormalities and are diploid in nature 
[36] initially we investigated that the non-senescent 
CAF of genetically stable tumours (CAF/GS-OSCC) 
did not by-pass senescence by treating them with 
cisplatin. Treatment of senescent CAF from genetically 
unstable tumours (CAF/GU-OSCC) with cisplatin 
further reinforced SA β-galactosidase activity and 
induced senescence in non-senescent CAF from 
genetically stable tumours (CAF/GS-OSCC)  (Fig 6A, 
Fig S6). Analysis of conditioned media collected from 
these cells revealed the senescent CAF/GU-OSCC 
released higher levels of MCP-1 and IL-6 than both 
non-senescent CAF/GS-OSCC and normal proliferating 
fibroblasts (Fig 6B-C). The senescent CAF/GU-OSCC 
were also able to induce more dysplastic and malignant 
cell migration and invasion than normal fibroblasts and 
non-senescent CAF/GS-OSCC, and this was augmented 
by cisplatin treatment (Fig 6D-F).  Examination of 
SASP-associated miRNA by qRT-PCR revealed levels 
of miR-335 was significantly elevated in senescent 
CAF/GU-OSCC compared to normal proliferating 
fibroblasts (n=4). Non-senescent CAF/GS-OSCC also 
demonstrated a significant but highly variable elevation 
of miR-335 compared to normal fibroblasts (Fig 6G). 
Analysis of PTEN protein expression in CAF by 
western blot showed the senescent CAF/GU-OSCC 
expressed significantly less PTEN protein compared to 
the non-senescent CAF/GS-OSCC and normal 
fibroblasts (Fig 6H-I).  
  




















































































































fibroblasts secreted  less  IL‐6  into  the conditioned media  (both senescent and proliferating)  (n=3)  (E). qRT‐PCR and western blot showed
COX‐2  inhibition  in senescent  fibroblasts  is associated with declined  transcript  levels of SASP associated miRNAs: miR‐335  (F)  (n=2) and


























































A similar reduction in PTEN expression was observed 
in senescent CAF isolated from colorectal cancer 





















































the adjacent non-cancerous bowel section of the same 
individuals underscoring its importance in stromal 





Senescent CAF/GU‐OSCC  (n=3)  secreted more MCP‐1  (B) and  IL‐6  (C)  than non‐senescent CAF/GS‐OSCC  (n=2) and normal  (n=4)  control
fibroblasts. Senescent CAF/GU‐OSCC stimulated migration of both D20 (D) and H357 cells (E) in vitro (n=3). Invasion of H357 cells was also
increased in presence of senescent‐CAF in organotypic models (BICR63, n=3) (F); immunohistochemistry for p16INK4A indicated senescence
in fibroblasts  incorporated  in the organotypic model. qRT‐PCR showed miR‐335 (G)  levels are elevated  in CAF of both GS‐OSCC (n=2) and
GU‐OSCC (n=4) tumours. Western blot showed PTEN expression was reduced in senescent CAF/GU‐OSCC (n=4) compared to non‐senescent

































































































































Although miR-335 levels demonstrated a trend towards 
an increase this failed to reach statistical significance in 
the cohort utilized (p=0.494) (Fig S7C).  
 
Determination of COX-2 activity in senescent CAF 
revealed COX-2 expression and PGE2 secretion was 
amplified in these cells compared to non-senescent-
CAF and normal fibroblasts (Fig 7A). PGE2 levels were 
further increased by treating these cells with cisplatin 
(Fig 7B), and this increase was inhibited by celecoxib 
(Fig 7C). Celecoxib treatment restored PTEN levels in 
senescent CAF/GU-OSCC to approaching the levels in 
proliferating normal fibroblasts (Fig 7D). Chemotaxis 
of cancer cells towards conditioned media derived from 
celecoxib treated senescent CAF was reduced and the 
intensity of fluorescence signal from α−SMA positive 
stress fibers became attenuated and less conspicuous in 




The tumour microenvironment is increasingly 
recognized as a potential target for novel therapeutics. 
This is hampered, however, by the lack of 
understanding of the mechanisms leading to the 
corruption of the predominant cell type in the tumour 
stroma, the fibroblast. Here we demonstrate widespread 
alterations in miRNA expression occur in fibroblasts 
induced to senesce by cisplatin, a widely used 
chemotherapeutic agent. These changes in miRNA 
expression coincide chronologically with the 
development of a pro-tumourigenic secretory phenotype 
(the senescence-associated secretory phenotype, SASP). 
We show that a miRNA elevated in concert with the 
development of the SASP, miR-335, contributes to the 
generation of a pro-inflammatory SASP by increasing 
the release of MCP-1, IL-6, and MMP-2, at least in part 
by down-regulating PTEN. The aberrant expression of 
miR-335 and PTEN is restored by treatment with 
celecoxib, a specific inhibitor of COX-2, indicating a 
role for prostaglandin signaling in the generation of the 
SASP in response to cisplatin. miR-335 was found to be 
up-regulated in CAF isolated from oral cancers, and this 
was associated with increased PGE2 secretion and 











The majority of reports of roles for microRNA in CAF 
to date have focused on the development of contractile, 
α-smooth muscle expressing myofibroblastic CAF [e.g. 
37]. Fewer studies have examined the contribution of 
microRNA to the secretory phenotype observed in 
senescent CAF. Bhaumik et al. identified up-regulation 
of miR-146a in senescent fibroblasts [18], and proposed 
its involvement in suppression of IL-6 by targeting 
IRAK1. Here we also observed up-regulation of miR-
146a but also identified aberrant expression of a number 
of other microRNA, including miR-335, associated with 
SASP development in primary human fibroblasts. In 
silico analysis indicated that PTEN was a putative target 
of miR-335, which was subsequently confirmed by 
reporter assay and analysis of PTEN protein levels in 
fibroblasts over-expressing miR-335. PTEN is a 
negative regulator of PI3 kinase/Akt signaling, 
originally identified as a tumour suppressor in epithelial 
cells [38]. Its function in mesenchymal cells is less well 
understood but it is reported to be a key regulator of 
myofibroblast differentiation [39]. Furthermore, PTEN 
is reported to be down-regulated in the stroma of breast 
and oropharyngeal tumours [40, 41] and to play a role 
in regulating stromal fibroblast-epithelial interactions, 
but the underlying mechanisms are unclear [27]. 
Although previously implicated in the development of 
senescence, this is the first study to identify a role for 
PTEN in regulating the SASP of senescent fibroblasts. 
The ability of PTEN-depleted fibroblasts to enhance 
tumour cell migration and its down-regulation in 
senescent CAF (derived from both oral and colorectal 
tumours) suggest that PTEN may be a critical modulator 
of pro-tumourigenic signaling in the tumour 
microenvironment and contribute to chemotherapy 
resistance and cancer recurrence or progression in 
patients receiving chemotherapy and radiotherapy. The 
mechanisms by which PTEN regulates the SASP 
remain obscure; in our system transient depletion of 
PTEN by siRNA resulted in a significant increase in the 
expression of MMP2 and a trend towards increasing 
secretion of IL-6 but not any other SASP factors. We 
suggest this may have been the result of the transient 
nature of the knockdown of PTEN; we are currently 
utilizing CRISPR to generate pten null fibroblasts and 
expression vectors to stably over-express PTEN in oral 
Cisplatin treatment increased PGE2 secretion by senescent CAF and normal fibroblasts (n=3) (B). Blockade of COX‐2 catalytic
activity diminished PGE2 secretion by normal fibroblasts and senescent CAF (n=3) (C). In contrast to normal fibroblasts (n=4),
senescent‐CAF  (n=3)  expressed  less  PTEN  protein  and  this  was  rescued  by  celecoxib  treatment  (D).  Celecoxib  treated
senescent CAF showed reduced capacity to stimulate paracrine migration of H357 cells in vitro, (n=3) (E). Celecoxib treatment
abrogated  activation of CAF  and  cisplatin‐induced premature  senescent  fibroblasts by extenuating  stress  fibers  formation
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fibroblasts in order to examine further the role of PTEN 
in the generation of the SASP. 
 
miR-335 was first described as a tumour suppressor and 
has since been ascribed roles in diverse pathologies 
such as depression and osteoarthritis [42, 43]. Notably, 
miR-335 has been implicated in the generation of 
senescence in mesangial cells [20] and mesenchymal 
stem cells [22]; in both of these studies, miR-335 was 
found to increase upon provocation of senescence, in 
keeping with our findings in primary fibroblasts. In 
addition, Tomé et al observed IL-6 and MCP-1 
secretion was increased in MSC over-expressing miR-
335 [22], further validating the suggestion that miR-335 
may play a key role in SASP generation. In our study, 
we observed no effect of miR-335 overexpression on 
the acquisition of markers of senescence, in contrast to 
the findings of Tomé et al, possibly reflecting 
differences between species and cell types in the 
functions of miR-335. In our study, miR-335 was 
expressed at higher levels on the provocation of 
senescence, and this increased with time, following a 
similar time course to the increase in secretion of SASP 
proteins. This, together with the observation that over-
expression of miR-335 increases the release of SASP 
factors, suggests miR-335 may be a novel regulator of 
the SASP. This hypothesis is further supported by 
elevated expression of miR-335 in senescent CAF, 
which also display an enhanced SASP. Surprisingly, 
miR-335 levels were also elevated, to a variable degree, 
in non-senescent CAF. We speculate this may reflect 
the inherent heterogeneity in the CAF phenotype 
compared to normal fibroblasts.  
 
We have previously shown that COX-2 expression 
increases aberrantly in cancer cells in response to 
stromal cues [44]. Although elevated prostaglandin 
generation by senescent cells has been reported [30], 
here we demonstrate that a selective COX-2 inhibitor 
can suppress the pro-inflammatory SASP of senescent 
CAF and normal fibroblasts, and to link COX-2 activity 
with PTEN  expression  levels  in  senescent  fibroblasts.  
Taken together these data suggest the existence of a 
novel mechanism, which in part appears to involve post-
transcriptional regulation of PTEN by miR-335, that 
could be susceptible to stromally-directed therapeutic 
intervention to ameliorate the off-target/bystander 




Cell culture. Normal human primary oral fibroblasts 
were extracted from gingiva of patients attending 
Charles Clifford Dental Hospital for tooth extraction 
(approved by Sheffield Research Ethics Committee; 
07/H1309/105), via collagen digestion and selective 
trypsinization. Normal oral fibroblasts, oral squamous 
cell carcinoma (OSCC) derived cell lines SCC4 and 
H357 and oral dysplasia derived cell line D20 (kindly 
provided by Dr K. Hunter, University of Sheffield, UK) 
and cancer-associated fibroblasts (CAF) derived from 
OSCC [36] were cultured in DMEM supplemented with 
10% (v/v) fetal calf serum (FCS) and 2 mM L-glutamine. 
All cultures were incubated at 37oC and 5% CO2. 
Normal dividing cells (presenescent or proliferating) had 
a cell cycle time of 48-54 hours and senescent cells, 
including senescent CAF, >14 days. CAF and control 
fibroblast from macroscopically normal tissue from 
colorectal cancer patients were kindly gifted by Professor 
John McCall from the Department of Surgical Science of 
Dunedin Hospital, New Zealand. This study had been 
approved by the Human Ethics Committee of the 
University of Otago (14/NTA/33).  
 
Induction of senescence. Early passage fibroblasts (10 
mean population doublings [8]) were induced to senesce 
prematurely with sub-cytotoxic doses of H2O2 (500 µM) 
for 2 h and cisplatin (10 µM) for 24 h. After completing 
the duration of treatments the fibroblasts were washed 
twice with 1X PBS (Sigma) and fresh normal growth 
media were added. The cells were then cultured for a 
time-point of 15 days with regular changes of media 
every 72 h in both the control and drug-induced 
fibroblasts. In parallel oral fibroblasts from the same 
patients were cultured and sub-cultured continuously 
until a mean population doublings of 80 (replicative 
exhaustion) to yield replicative senescent cells [8] 
(>85% cells are positive for senescence associated β-
galactosidase activity). Acquisition of senescence was 
examined by analyzing senescence associated β-
galactosidase (SA β-Gal) activity at day 15 post-
treatment with genotoxic stimuli and on replicative 
senescent oral fibroblasts.  In addition, qPCR and 
immunocytochemistry were used to analyze the levels 
of cell cycle markers p16INK4A and p21CIP1, respectively, 
as described below. 
 
Transient transfection of fibroblasts. fibroblasts (5 X 
105) were seeded in T25 flasks and incubated overnight. 
These cells were either transfected with non-targeting 
miRNA negative control and specific synthetic miRNA 
precursors (Life Technologies) or with PTEN siRNA 
and silencer Cy3 labelled negative control 1 siRNA 
(Life technologies) at a final concentration of 50 nM 
using Oligofectamine 2000 (Life Technologies) in 
reduced serum media. Total RNA and protein were 
extracted at 72 h post-transfection. 
 
Luciferase reporter assay. A 1345 bp fragment of the 
PTEN 3’UTR containing the putative binding site for 
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miR-335 was amplified from cDNA extracted from 
primary oral fibroblasts using the following primers: 
forward 5’ ACTGAACTAGTTGTTGACACGTTTTCC 
ATACCTT 3’  and  reverse 5’ TTATTGAGCTCGGGA 
TGAGGCATTATCCTGTACAC 3’. Amplicons were 
digested with Sac I and Spe I and ligated into pmiR-
Report (Life Technologies), immediately downstream 
of the firefly luciferase coding region under the control 
of the CMV promoter. The recombinant plasmid, pmiR-
PTEN (1 μg) was co-transfected with pSV-β-
galactosidase control vector (0.6 μg) along with control 
non-targeting miRNA or miR-335 precursor (50 nM) 
using Fugene HD (Promega), according to the 
manufacturer’s instructions. After 48 h incubation, cells 
were washed with PBS and lysed using reporter lysis 
buffer (Promega). Luciferase activity was measured 
using the Stop and Glo assay (Promega), according to 
the manufacturer’s instructions. This was normalized to 
the β-galactosidase activity of the same sample using 
the β-galactosidase Enzyme Assay System (Promega) 
according to the manufacturer’s protocol.  
 
Preparation of conditioned medium. Fibroblasts were 
washed twice with PBS and incubated in serum-free 
media at 370 C for 24 h. In cisplatin-treated and 
miRNA/siRNA transfected oral fibroblasts conditioned 
medium (CM) was prepared at day 15 post-treatment 
and 24 h post-transfection, respectively. Prior to 
performing every functional assay and measuring the 
levels of secreted cytokines and MMP-2 activity the 
CM of the senescent and presenescent fibroblasts were 
normalized to the cell density of 5 x 105 per ml of CM. 
The synthetic oligonucleotide mimics had no effect on 
fibroblast proliferation and CM normalization to 
biomass (cell number) was not required.   
 
Tiling low-density arrays. Total RNA was extracted 
using mirVana miRNA isolation kit (Life 
Technologies). miRNA expression profiling was 
performed using commercially available Tiling Low-
Density Array; TLDA (Life Technologies) which 
comprises of hybridization of pre-amplified cDNA 
against 754 human miRNA assays labeled onto 
microfluidic cards by TaqMan qRT-PCR. The raw data 
were extracted using RQ manager version 1.2.1 and 
analyzed by Data Assist Software version 3.0 (Life 
Technology). The ΔCt values were normalized to U6 
endogenous control at a Ct cut-off value of 34. Fold 
change of the differentially expressed miRNAs were 
calculated from ΔΔCt values relative to the 
presenescence control. 
 
miRNA and gene expression assays. Following cDNA 
synthesis TaqMan and SYBR-Green probes and primers 
(Life Technologies) were used to validate candidate 
miRNAs and gene expression changes respectively in 
presenescent and prematurely senescent oral fibroblasts 
by qRT-PCR. The ΔCt values were calculated by 
normalizing to U6 and RNU48 endogenous controls. 
The ΔΔCt values of target genes were calculated by 
normalizing their levels to presenescence control. The 
mRNA expression is represented graphically as the 
mean fold change (2-ΔΔCt). 
 
Human cytokine antibody array. The soluble cytokines 
of SASP from cisplatin-treated and presenescent oral 
fibroblasts were determined by human cytokine 
antibody array 6 (Raybiotech). The signal intensities 
were quantified using 1D gel analysis software 
(BioRad). 
 
MCP-1, IL-6, and PGE2 ELISA.  Human MCP-1 and 
IL-6 ELISA development kit (Peprotech) were used to 
analyze the levels of secreted MCP-1 and IL-6 in CM 
obtained from presenescent and cisplatin treated oral 
fibroblasts according to manufacturer’s protocol. 
Secreted levels of human PGE2 were determined using 
competitive ELISA (R&D system; KGE004B) 
according to manufacturer’s instruction.  
 
Proliferation assay. SCC4, H357 and D20 cells were 
seeded down at 5 x 103 per 100 μl of DMEM into each 
well of a 96-well plate. The cells were serum starved 
overnight and subsequently treated with freshly 
prepared CM of senescent and presenescent oral 
fibroblasts. The rate of proliferation was measured at 
time points 0 - 120 h, using CyQuant NF cell 
proliferation assay kit (Invitrogen, #C35006) according 
to the guidance of the manufacturer. Fluorescence was 
recorded at an excitation of 485 nM and emission 
detection at 530 nm using a microplate reader (Tecan). 
    
Migration and invasion assays. SCC4, H357 and D20 
cells were serum starved overnight prior to 
experimentation. Cells were trypsinized and 
resuspended in DMEM containing 0.1% (w/v) BSA at 5 
x 105 cells/ml. Cell suspension (200 µL) was pipetted 
into the top of the transwell chamber with/without 
matrigel coating and CM was added to the lower 
chamber. For blockade of secreted MCP-1, CM was 
incubated with either anti-MCP-1 antibody (20 
μγ/ml, subtype IgG, R&D: MAB679) or isotype IgG1 
and IgG2 controls (Serotec: MCA1209, Invitrogen: 
MG2b00) 1 h preceding chemotaxis assay.  SCC4 and 
D20 cells were allowed to migrate for 20 h and H357 
cells for 40 h. The cells were then swabbed away from 
the inside of the transwell chamber and the cells 
adhering to the underside of the chamber were fixed 
with 100% (v/v) methanol. Migrated cancer and 
dysplastic cells were stained with 0.1% (w/v) crystal 
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violet. The cells were counted by light microscopy at 
40x magnification. Three fields of view from each 
insert were counted. Invasion was measured from 
invasive index using the formula:  
 
Ii = |(Tm(t)-Ti(t))|/|(Tm(c)-Ti(c))| 
 
where Ii stands for invasive index, Ti is the total number 
of invading cells, Tm is the total number of migrated 
cells, t is treatment with different types of CM and c is 
control.  
 
A modified 3D organotypic model [16] was used to 
examine the invasive potential of H357 cell lines into 
the human de-epithelialized dermis in the presence of 
normal, cisplatin-induced and CAF (manuscript under 
preparation). The model was grown in an air-liquid 
interface for 14 days. These were then formalin (10%) 
fixed, paraffin embedded and microdissected. 
Haematoxylin and eosin staining of tissue sections were 
used to assess the depth of invasion of cancer cells. 
   
Western blot analysis. Oral fibroblasts were lysed in 
RIPA lysis buffer (Sigma) supplemented with protease 
and phosphatase inhibitor cocktail (Roche) and 
benzonuclease (Sigma). Protein was quantified by 
Pierce BCA protein assay kit (Thermoscientific). 
Membranes were incubated with human rabbit 
monoclonal antibody for total PTEN (#9559), pan-AKT 
(#4691), phospho-AKT (ser473) (#4060) and phospho-
AKT (thr308) (#2965) and GAPDH (#G9545) (Cell 
Signaling) at 1 in 1000 and human mouse monoclonal 
antibody β-actin (Sigma) at 1 in 10000. Mouse and 
rabbit IgG conjugated with horseradish peroxidase 
(Sigma, 1 in 3000) were used as secondary antibody. 
Chemiluminescence was recorded on X-ray films using 
an automated X-ray film processor (Xograph imaging 
systems). Band densitometry was analyzed using 1D gel 
analysis software (BioRad).  
 
Gelatin zymography.  Fresh conditioned media was 
collected from fibroblasts and concentrated using 
vivaspin-500 5 kDa cut-off spin columns (Sartorius, 
#VS0101) by centrifugation at 10,000 rpm for 15 m. 
Concentrated conditioned media from senescent and 
presenescent fibroblasts were mixed with 2X non-
reducing zymography sample loading buffer (Tris-HCl, 
200 mM; SDS, 2% (w/v); glycerol, 20% (v/v) and 
bromophenol blue 0.1% (w/v), pH 6.8), and incubated 
for 30 min at 37oC. Samples were electrophoresed in 
polyacrylamide gels containing gelatin (10% (w/v)). 
Following electrophoresis gels were allowed to renature 
in 2.5% (v/v) Triton X-100 in PBS for 1 h and 
maintained in zymogram developing buffer; 0.5 M Tris, 
2 M NaCl (BDH GPR), 50 mM CaCl2 (Sigma), 50 μM 
ZnCl2 (Sigma), 1% (v/v) Triton X-100, pH=7.5; at 37oC 
for 24 h with gentle agitation. Gels were then stained 
with Coomasie brilliant blue R-250 for 30 m and 
destained with 40% (v/v) methanol and 10% (v/v) 
glacial acetic acid until distinct faint bands became 
visible. Fisher Scientific’s EZ-Run pre- stained Rec 
protein ladder was used as molecular weight markers. 
Gelatinase activity was determined using Quantity One 
1D gel software (BioRad; version 4.5.0) and the 
intensity of bands were divided by the total number of 
fibroblasts present in each sample of conditioned 
medium to normalize to cell density.  
 
Immunocytochemistry and histological analysis. 
Paraffin-embedded tissues were deparaffinised. 
Microwave heat mediated antigen retrieval in citrate 
buffer was required for p16INK4A (JC8, Santa Crutz, 1 in 
100 in 0.5% normal horse serum) antibody. The tissue 
sections were counterstained using haematoxylin. 
Fibroblast activation was determined by direct immuno-
fluorescence cytochemistry for α-SMA using FITC 
conjugated anti-mouse monoclonal α-SMA antibody 
(Sigma, 1 in 100 dilutions in 5% bovine serum 
albumin). The fixed cells were mounted in DAPI rich 
Prolong Gold anti-fade reagent and fluorescence was 
observed in Zeiss microscope (Axioplan 2 imaging) and 
photographed using image pro-plus software version 
7.0.1, at 40X magnification. Fluorescence intensity 
was quantified using NHS Image J software (version 
1.49). 
 
Inhibition of COX-2 activity. Senescent and non-
senescent oral fibroblasts were treated with the selective 
COX-2 inhibitor celecoxib (1 μM) for 48 h in serum 
free DMEM. Untreated cells were used as the control.  
 
Bioinformatics database mining. Target Scan version 
6.2 (www.targetscan.org) and miRwalk (www.umm.uni-
heidelberg.de/apps/zmf/mirwalk/ ) were used to predict 
putative gene targets of candidate miRNA of interest. 
DIANA-miRPath online tool version 2.0 was used to 
predict the miRNA-targeted pathways that are altered in 
senescent fibroblasts.  
 
Statistical analysis. Sigma Plot (version 12) was used to 
determine statistical significance. One-way ANOVA, 
Two-way ANOVA, ANOVA with repeated measures 
and paired student’s t-test were used to analyze data. 
Appropriate posthoc corrections were used according to 
data distribution and experimental procedures as 
described in figure legends. Mann-Whitney U-test was 
performed when data were not normally distributed. P-
value <0.05 was considered as statistically significant 
wherein *p<0.05, **p<0.01 and ***p<0.001. 
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oral  fibroblasts post‐induction of senescence demonstrated a gradual  increase  in the amounts of MMP‐2  in senescent  fibroblasts during
acquisition of senescence and establishment of SASP (A). The conditioned media were normalized to 5 X 105 cells/ml. In addition, qRT‐PCR
(B)  and  gelatin  zymography  (C)  in  fibroblasts  induced  to  senesce  using  different  stimuli  corroborated with  initial  findings  and  further
showed  senescent  oral  fibroblasts  synthesized  and  secreted  more  active  MMP‐2  than  presenescent  proliferating  controls  (n=3).
Prematurely senescent oral fibroblasts also expressed and secreted more MCP‐1 (D‐E) and IL‐6 (F‐G) than proliferating controls, confirmed
by qRT‐PCR and ELISA. Despite of having lower MCP‐1 and IL‐6 mRNA levels, the replicative senescent fibroblasts secreted more of these










































































































talk  between  senescent  oral  fibroblasts  and 
cancer  cells  does  not  demonstrate  cell  line
specificity.  Soluble  factors  secreted  into
conditioned  media  of  senescent  fibroblasts 
stimulated  proliferation  (A)  and  migration  (B)  of 
another  oral  squamous  cell  carcinoma  derived  cell 
line  SCC4  in  vitro  (n=3).  All  experiments  were 
performed independently as indicated by n and with 
technical repeats.  The data represents mean ± SEM 
of  three  independent  experiments  in  triplicate. 
*p<0.05,  for  proliferation  assay  the  data  were 
analyzed  by  two‐way  repetitive  measure  ANOVA
with post‐hoc corrections by Holm‐Sidak method (A)
and  for migration assay  the data were analyzed by 
one‐way  ANOVA  with  post‐hoc  corrections  by 
Dunn’s method (B).  
Figure S3. The pro‐tumourigenic SASP of senescent fibroblasts is associated with differential expression of miRNAs. qRT‐PCR





and with  technical  repeats.  The  data  represents mean  ±  STDEV  (A‐D)  or mean  ±  SEM  of  three  independent  experiments  in  triplicate.
*p<0.05, by one‐way ANOVA with post‐hoc corrections by Holm‐Sidak method (A‐C),  paired student’s t‐test (D‐G). 
  




































































































Figure S4. miRNA pathway analysis showing  the gene  targets of miRNAs  interacting with PI3 Kinase/Akt pathway  in
senescent fibroblasts and the effect of transient knockdown of PTEN on IL‐6 expression in oral fibroblasts. DIANA miR‐
Path analysis  tool was used  to predict and  identify  the gene  targets of differentially expressed miRNAs affecting  the PI3 kinase/Akt
pathway in senescent fibroblasts wherein yellow highlights indicate genes targeted by one miRNA, orange indicates genes targeted by
two miRNAs and red indicates genes targeted by three or more miRNAs (A‐B). qRT‐PCR analysis of cDNA synthesized from fibroblasts
having transient knockdown of PTEN demonstrated no significant difference  in  IL‐6 mRNA  levels  in comparison to control fibroblasts
transfected with non‐targeting siRNA, n=3 (C). All experiments were performed independently as indicated by n and with technical repeats.
  





































































































Selective  inhibition of COX‐2  activity with  celecoxib  (1μM)  in  senescent  fibroblasts  failed  to  reduce  secretion of
MCP‐1 (A) and MMP‐2 (B) into the conditioned media (n=3). Celecoxib did not stimulate senescence in proliferating




phenotype  of  senescent  CAF/GU‐OSCC.  SA‐β‐gal  activity was  assessed  in  CAF  treated with  cisplatin  and
untreated control. The number of SA‐β‐gal positive cells (blue) was counted and the intensity of blue colour per
cell was  also measured using  Image  J  software  (version  1.49)  to determine  senescence  reinforcement. Paired
student’s t‐test was used to determine statistical significance. *p<0.05 was considered statistically significant.  
  













































































































































































































Table  S1.  Differentially  expressed  miRNAs  in  cisplatin  induced  senescent  fibroblasts  compared  to 
presenescent proliferating control.  
 







hsa-miR-223 705.1190 0.3724 
hsa-miR-939 327.6360 0.3726 
hsa-miR-1243 251.7600 0.3541 
hsa-miR-663B 147.8170 0.3512 
hsa-miR-590-3P 120.9350 0.3762 
hsa-miR-452# 109.6670 0.3729 
hsa-miR-184 54.1033 0.2097 
hsa-miR-1204 50.8617 0.3680 
hsa-miR-888 37.2999 0.1824 
hsa-miR-875-5p 33.0642 0.3868 
hsa-miR-1288 30.9889 0.2175 
hsa-miR-363# 26.9167 0.3697 
hsa-miR-512-3p 24.8025 0.0796 ** 
hsa-miR-1302 21.4167 0.3686 
hsa-miR-517a 15.3168 0.0011 *** *** *** 
hsa-miR-645 14.8657 0.4024 
hsa-miR-361-3p 14.0477 0.1279 
hsa-miR-606 13.6667 0.3654 
hsa-miR-662 13.5833 0.3739 
hsa-miR-922 13.0833 0.3739 
hsa-miR-520h 12.1015 0.3824 
hsa-miR-148b 11.8641 0.3202 
hsa-miR-943 11.8363 0.3397 
hsa-miR-133a 11.8127 0.3559 
hsa-miR-519b-3p 11.4114 0.2994 
hsa-miR-885-5p 11.2683 0.0798 
hsa-miR-1292 11.0930 0.3842 
hsa-miR-517c 10.5354 0.0111 * *** 
hsa-miR-944 10.2789 0.3838 
hsa-miR-1238 10.0833 0.3739 
hsa-miR-586 9.7105 0.4175 
hsa-miR-124# 9.6545 0.3614 
hsa-miR-200a 9.3425 0.3882 
hsa-miR-1296 9.1140 0.3598 
hsa-miR-638 8.8922 0.3959 
hsa-miR-141# 8.2500 0.3589 
hsa-miR-29b-2# 8.2254 0.4046 
hsa-miR-519a 8.2154 0.0364 * ** 
hsa-miR-1228# 8.2001 0.4093 
hsa-miR-1206 8.0938 0.3854 
  




































































































hsa-miR-1291 8.0446 0.3512 
hsa-miR-23a 7.8395 0.3994 
hsa-miR-206 7.6997 0.0993 
hsa-miR-891a 7.5516 0.2486 
hsa-miR-216b 6.7836 0.0636 
hsa-miR-202# 5.9830 0.4358 
hsa-miR-205 5.9156 0.1843 
hsa-miR-1262 5.8348 0.1545 
hsa-miR-548J 5.6334 0.4514 
hsa-miR-508-3p 5.4649 0.0682 ** 
hsa-miR-608 5.3745 0.1733 
hsa-miR-892b 5.2233 0.2832 
hsa-miR-186# 4.7706 0.4258 
hsa-miR-489 4.4804 0.1189 
hsa-miR-503 4.4286 0.3429 
hsa-miR-520b 4.3208 0.3626 
hsa-miR-1208 4.2500 0.3401 
hsa-miR-363 4.1806 0.2905 
hsa-miR-1283 4.0391 0.4318 
hsa-miR-375 4.0066 0.3304 
hsa-miR-432# 3.9618 0.4897 
hsa-miR-337-3p 3.8538 0.4805 
hsa-miR-485-5p 3.8510 0.2738 
hsa-miR-1252 3.8056 0.3989 
hsa-miR-708# 3.6667 0.3325 
hsa-miR-668 3.6375 0.5055 
hsa-miR-664 3.5373 0.2048 
hsa-miR-380 3.5164 0.4186 
hsa-miR-449a 3.4240 0.2277 
hsa-miR-9# 3.4112 0.1756 
hsa-miR-522 3.2896 0.2398 
hsa-miR-302c 3.2708 0.3264 
hsa-miR-1245 3.2424 0.5132 
hsa-miR-377# 3.2379 0.3263 
hsa-miR-596 3.1857 0.4647 
hsa-miR-149# 3.1627 0.3412 
hsa-miR-92b# 3.0329 0.1659 
hsa-miR-1305 3.0206 0.5348 
hsa-miR-335 2.9835 0.0032 ** *** 
hsa-miR-125b-2# 2.8790 0.3429 
hsa-miR-544 2.8605 0.1739 
hsa-miR-146a 2.8174 0.0031 ** *** 
hsa-let-7c# 2.7549 0.2381 
  



































































































hsa-miR-1269 2.7533 0.4819 
hsa-miR-33a 2.7118 0.4417 
hsa-miR-549 2.7037 0.4294 
hsa-miR-1290 2.7032 0.1722 
hsa-miR-938 2.6943 0.0355 * 
hsa-miR-620 2.6696 0.0443 * 
hsa-miR-302a# 2.6580 0.4943 
hsa-miR-219-5p 2.6334 0.2336 
hsa-miR-137 2.6076 0.0119 * ** 
hsa-miR-34a# 2.5690 0.0124 * ** 
hsa-miR-1276 2.5607 0.5386 
hsa-miR-1254 2.5533 0.1846 
hsa-miR-34b 2.5217 0.3854 
hsa-miR-105# 2.4969 0.3282 
hsa-miR-181c# 2.4916 0.4524 
hsa-miR-30a-5p 2.4895 0.3112 
hsa-miR-541 2.4474 0.2580 
hsa-miR-34a 2.4435 0.0288 * ** 
hsa-miR-24-1# 2.4386 0.4998 
hsa-miR-372 2.4304 0.2921 
hsa-miR-378 2.4265 0.1108 
hsa-miR-148a 2.3945 0.2100 
hsa-miR-302a 2.3877 0.5263 
hsa-miR-500 2.3729 0.5121 
hsa-miR-129# 2.3512 0.5045 
hsa-miR-1825 2.3082 0.2735 
hsa-miR-449b 2.3028 0.3194 
hsa-miR-1248 2.2801 0.2921 ** 
hsa-miR-519d 2.2316 0.3407 
hsa-miR-23b 2.2083 0.3494 
hsa-miR-654-5p 2.1972 0.0883 
hsa-miR-99a# 2.1900 0.1765 
hsa-miR-148a# 2.1783 0.3760 
hsa-miR-486-5p 2.1572 0.3145 
hsa-miR-1274A 2.1451 0.0302 * ** 
hsa-miR-1179 2.1444 0.0713 
hsa-miR-624 2.1427 0.3127 
hsa-miR-770-5p 2.1283 0.4983 
hsa-miR-7-2# 2.1159 0.3265 
hsa-miR-577 2.1074 0.3560 
hsa-miR-941 2.1024 0.5186 
hsa-miR-1270 0.4994 0.0679 
hsa-miR-25# 0.4978 0.1165 
hsa-miR-30d# 0.4891 0.0194 * 
  



































































































hsa-let-7a# 0.4817 0.0139 * 
hsa-miR-661 0.4805 0.0458 * 
hsa-miR-130b# 0.4723 0.0012 ** ** 
hsa-miR-1324 0.4640 0.0561 
hsa-miR-888# 0.4516 0.2183 
hsa-miR-144 0.4341 0.1189 
hsa-miR-504 0.4282 0.0095 ** 
has-miR-155 0.4198 0.0154 * 
hsa-miR-10a 0.4088 0.0368 * 
hsa-miR-182 0.3945 0.0364 * 
hsa-miR-16-1# 0.3906 0.0010 *** ** 
hsa-miR-603 0.3878 0.1188 
hsa-miR-516-3p 0.3803 0.0466 * 
hsa-miR-17# 0.3789 0.0337 * 
hsa-miR-497# 0.3714 0.1172 
hsa-miR-132# 0.3705 0.0603 
hsa-miR-548K 0.3618 0.1168 
hsa-miR-634 0.3508 0.1162 
hsa-miR-219-1-3p 0.3367 0.0034 ** 
hsa-miR-15a# 0.3341 0.0000 *** *** 
hsa-miR-524 0.3222 0.0447 * 
hsa-miR-630 0.3155 0.0655 
hsa-miR-15b# 0.2943 0.0051 ** 
hsa-miR-597 0.2913 0.0033 ** 
hsa-miR-1183 0.2834 0.0042 ** 
hsa-miR-101# 0.2700 0.0000 *** *** 
hsa-miR-144# 0.2635 0.0000 *** ** 
hsa-miR-580 0.2552 0.0413 * 
hsa-miR-1289 0.2510 0.0361 
hsa-miR-600 0.2414 0.0062 ** 
hsa-miR-483-3p 0.2311 0.0024 ** 
hsa-miR-643 0.2264 0.0005 *** ** 
hsa-miR-548d-3p 0.1953 0.0014 ** 
hsa-miR-566 0.1685 0.0000 *** ** 
hsa-miR-135b# 0.1651 0.0005 *** 
hsa-miR-644 0.1324 0.0010 *** 
hsa-miR-1278 0.0956 0.0000 *** ** 
hsa-miR-23a# 0.0791 0.0003 *** 
hsa-miR-1285 0.0759 0.0001 *** 
miRNA  that were either up‐regulated or down‐regulated by 2‐fold  in  cisplatin  induced  senescent  fibroblasts. The 











































































































KEGG pathway p-value #genes #miRNAs 
PI3K-Akt signaling pathway 1.24E-35 158 28 
Pathways in cancer 1.93E-36 165 28 
Focal adhesion 9.74E-33 100 28 
Neurotrophin signaling pathway 3.88E-28 70 28 
HTLV-I infection 4.87E-16 117 28 
Chemokine signaling pathway 2.28E-07 77 28 
Tight junction 1.54E-05 59 28 
MAPK signaling pathway 6.28E-36 127 27 
Melanogenesis 1.36E-06 45 27 
Transcriptional misregulation in cancer 3.66E-06 80 27 
Viral carcinogenesis 0.002974748 80 27 
Protein processing in endoplasmic reticulum 0.007563723 67 27 
Wnt signaling pathway 1.92E-28 81 26 
Hepatitis B 9.59E-27 76 26 
Ubiquitin mediated proteolysis 5.83E-20 68 26 
Axon guidance 8.59E-20 69 26 
Renal cell carcinoma 1.31E-19 42 26 
Dopaminergic synapse 2.01E-16 64 26 
Endometrial cancer 2.83E-13 31 26 
Glutamatergic synapse 2.06E-05 53 26 
Epstein-Barr virus infection 0.000155449 82 26 
Tuberculosis 0.01557663 66 26 
Herpes simplex infection 0.04133367 70 26 
Prostate cancer 5.54E-23 57 25 
Colorectal cancer 1.13E-17 41 25 
Gap junction 1.10E-14 45 25 
Regulation of actin cytoskeleton 4.70E-10 93 25 
Retrograde endocannabinoid signaling 3.30E-09 53 25 
T cell receptor signaling pathway 1.24E-07 48 25 
Influenza A 4.03E-05 69 25 
RNA transport 0.000593956 61 25 
Oocyte meiosis 0.000955549 51 25 
ErbB signaling pathway 1.09E-23 55 24 
Insulin signaling pathway 1.39E-23 68 24 
Glioma 4.22E-16 41 24 
HIF-1 signaling pathway 6.83E-15 54 24 
Long-term potentiation 1.92E-14 36 24 
GnRH signaling pathway 4.03E-13 44 24 
mRNA surveillance pathway 1.24E-10 43 24 
Measles 4.36E-09 64 24 
Amoebiasis 4.52E-09 47 24 
B cell receptor signaling pathway 6.88E-09 36 24 
Cholinergic synapse 9.83E-07 52 24 
Serotonergic synapse 0.00618267 44 24 
Endocytosis 8.30E-32 102 23 
Pancreatic cancer 1.69E-20 46 23 
Melanoma 5.81E-16 38 23 
mTOR signaling pathway 1.15E-13 34 23 
Osteoclast differentiation 5.88E-12 60 23 
Basal cell carcinoma 3.74E-09 27 23 
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Table S3. Seed sequences of differentially expressed miRNA  in senescent oral 
fibroblasts  predicted  to  target  the  PTEN  3’UTR.  The  seed  sequences  were 
obtained by in silico analysis using targetscan.org, version 6.2.  
 
miRNA Region and seed sequence 
miR-137 4005-4011     5’ UGCAAUAAU 3’ 
                  |||||| 
miR-137       3’ UCGUUAUU  5’ 
miR-148b 2254-2260     5’UUUUGCACUGU 3’ 
                | ||||||||| 
 miR-148b     3’ACUACGUGACU 5’  
 
3151-3158    5’UAUGCACUGA 3’ 
               |||||||||| 
 miR-148b    3’CUACGUGACU 5’  
 
miR-29b 676-683       5’ UUGGUGCUA 3’         
                  |||||||  
miR-29b-3p    3’ UACCACGAU 5’ 
 
1741-1747     5’ UUGGUGCUG 3’ 
                  ||||||| 
miR-29b-3p    3’ UACCACGAU 5’ 
miR-200a 1467-1473     5’ GCAGUGUUG 3’ 
                  ||||||| 
miR-200a-3p   3’ –GUCACAAU 5’ 
 
3257-3263     5’ UAGUGUUAU 3’ 
                  ||||||   
miR-200a-3p   3’ GUCACAAU  5’ 
 
4252-4258     5’ CCAGUGUUU 3’ 
                 |||||||   
miR-200a-3p   3’ UGUCACAAU 5’  
miR-519a 413-419       5’ UUGCACUUG 3’ 
                  ||||||| 
miR-519a-3p   3’ UACGUGAAA 5’ 
 
1148-1155     5’ AUGCACUUA 3’ 
                  ||||||| 
miR-519a-3p   3’ UACGUGAAA 5’         
